A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms APOLLO
- 05 Jun 2018 Trial design data presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.